Brief: Avadel Pharmaceuticals Announces Data Supporting Clinical Profile for LUMRYZ (sodium oxybate) For Extended-Release Oral Suspension
20/10/2023 13:15
Oct 20 (Reuters) - Avadel Pharmaceuticals PLC AVDL.O :
* AVADEL PHARMACEUTICALS ANNOUNCES DATA SUPPORTING CLINICAL
PROFILE FOR LUMRYZ™ (SODIUM OXYBATE) FOR EXTENDED-RELEASE ORAL
SUSPENSION (CIII) AT WORLD SLEEP 2023
Source text for Eikon: ID:nGNX313fcv
Further company coverage: AVDL.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Avadel Pharmaceuticals
See all newsBrief: Alkermes PLC Completes Acquisition Of Avadel Pharmaceuticals PLC, Accelerating Entry Into Sleep Medicine Market
NASDAQ TRADE HALT TRADING HALTED; FOR INFORMATION REQUESTED BY NASDAQ AT 08:10 AM
H Lundbeck steps down from takeover for Avadel, shares rise 3%
Deals of the day-Mergers and acquisitions
U.S. STOCKS ON THE MOVE-Viking, Valvoline, Alphabet